FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma

"Meanwhile, the FDA has also approved the Investigational New Drug (IND) application for a global Phase III trial of Toripalimab in combination with Axitinib versus Pembrolizumab for the first-line treatment of patients with advanced mucosal melanoma (Combination Clinical Trial)..."

012421- FDA Grants Toripalimab Fast Trac

.

Download • 85KB